Navigation Links
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
Date:9/2/2008

gy research strategy and overseeing all aspects of oncology research. While at Pfizer, Dr. O'Connor also built and oversaw the diabetes and obesity research groups at the La Jolla campus. His managerial duties encompassed the generation of new drug targets, the selection of development candidates, and strategic and scientific support for Phase 1 and 2 clinical studies. Prior to joining Pfizer, Dr. O'Connor served as a Fogarty Fellow at The National Cancer Institute, Bethesda, Maryland from 1988 to 1998. He is on the Editorial Board of Cancer Research and is a member of numerous scientific and medical professional organizations. Dr. O'Connor received his BSc degree in Pharmacology from Bradford University, England, and his PhD in Experimental Oncology Therapeutics from Manchester University, England.

Michael J. LaBarre will oversee all of Halozyme's product development efforts, bringing strong experience in chemistry, manufacturing and controls (CMC) based on his extensive experience in the biotechnology industry for both biologics and small molecules. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount's portfolio. Prior to joining Paramount, Dr. LaBarre served in various research and development positions at Biogen Idec (previously IDEC) from 1995 to 2006 where he had responsibility for analytical and formulation development, protein purification, and biochemical characterization supporting numerous IND and BLA submissions, including those for Rituxan(R) and Zevalin(R). His last position with Biogen Idec was Director of Analytical and Protein Biochemistry. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group. He began his career at Hybritech where he held positions in regulatory affairs and manufacturing technical support, focusing on radiolabeled antibody technologies and analy
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
3. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
7. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
8. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
11. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... 17 , - New ... Short-Term Mortality Compared to Previous Treatments , ... positive final results,from a Phase II trial of its ... acute myeloid leukaemia (AML). In the,trial, elacytarabine showed statistically ...
... , SHANGHAI, June 17 ... ("China-Biotics", "the Company"), a leading Chinese firm,specializing in ... products, today announced it will join the Russell,3000(R) ... its comprehensive set of U.S. and global equity ...
... (Nasdaq: PRXL ) announced today it will be ... Boston. James Winschel, Senior Vice President & Chief Financial ... 10:15 a.m. EDT on Tuesday, June 23, 2009. ... be available through the "Investor Relations - Upcoming Events" ...
Cached Biology Technology:Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7China-Biotics, Inc. to Join Russell 3000 Index 2China-Biotics, Inc. to Join Russell 3000 Index 3PAREXEL International to Present at the Wachovia Equity Conference 2
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... July 2, 2015 Fingerprint Cards has ... FPC1145 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... will be used by smartphone manufacturers in Asia ... in the communicated revenue guidance of approximately 2,200 MSEK for ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... ability to promote agricultural and conservation successes in the ... scientists, understanding of how plants adapt to local climate. ... study in the Oct. 7, 2011 issue of ... adaptations to local climate. The National Science Foundation ...
... Agrarian Research (IVIA, Spain) have created a machine that ... segments according to their quality and another that helps ... use computer vision to automatically inspect the fruits. ... dark rooms with the help of ultraviolet light that ...
... York Stem Cell Foundation (NYSCF) announced today that a British ... first recipient of The New York Stem Cell Foundation ... annually for extraordinary achievement in translational stem cell research. ... Director of the London Project to Cure Blindness and Professor ...
Cached Biology News:Oranges and mandarins are inspected using artificial vision 2Oranges and mandarins are inspected using artificial vision 3Professor Peter J. Coffey's stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012 2Professor Peter J. Coffey's stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012 3
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: